Population-level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis

Melanie Drolet, Elodie Benard, Marie-Claude Boily, Hammad Ali, Louise Baandrup, Heidi Bauer, Simon Beddows, Jacques Brisson, Julia M L Brotherton, Teresa Cummings, Basil Donovan, Christopher K Fairley, Elaine W Flagg, Anne M Johnson, Jessica A Kahn, Kimberley Kavanagh, Susanne K Kjaer, Erich V Kliewer, Philippe Lemieux-Mellouki, Lauri Markowitz & 10 others Aminata Mboup, David Mesher, Linda Niccolai, Jeannie Oliphant, Kevin G Pollock, Kate Soldan, Pam Sonnenberg, Sepehr N Tabrizi, Clare Tanton, Marc Brisson

Research output: Contribution to journalArticle

343 Citations (Scopus)

Abstract

Human papillomavirus (HPV) vaccination programs were first implemented in 2007. We conducted a systematic review and meta-analysis to examine the population-level impact and herd effects following female HPV vaccination programs, to verify whether the high efficacy measured in randomized controlled clinical trials are materialising under real-world conditions. We searched Medline and Embase databases (01/2007-02/2014), and conference abstracts for time- trend studies examining changes, between the pre- and post-vaccination periods, in the incidence/prevalence of at least one HPV-related endpoint: HPV infection, anogenital warts (AGW), and high-grade cervical lesions. We derived pooled relative risk (RR) estimates using random effect models. We stratified all analyses by age and gender. We performed subgroups analysis by comparing studies according to vaccine type, vaccination coverage and years since vaccination implementation. We assessed heterogeneity across studies using I2 and χ2 statistics. We performed trends analysis to examine dose-response between HPV vaccination coverage and each study effect measure. We identified 20 eligible studies, conducted in nine high-income countries, and representing >140 million person-years of follow-up. In countries with female vaccination coverage ≥50%, HPV-16/18 infections and AGW decreased significantly between the pre- and post-vaccination periods by 68% (RR=0·32, 95%CI[0·19;0·52]) and 61% (RR=0·39, 95%CI[0·22;0·71]), respectively, among females <20 years. Significant reductions in HPV-31/33/45 among females <20 years (RR=0·72, 95%CI[0·54;0·96]), and AGW among males <20 years (RR=0·66, 95%CI[0·47;0·91]) and older females (RR=0·68, 95CI[0·51;0·89]) were also observed, respectively suggesting cross-protection and herd effects. In countries with female vaccination coverage <50%, significant reductions were observed for HPV-16/18 infection (RR=0·50, 95%CI[0·34;0·74]) and AGW (RR=0·86, 95%CI[0·79;0·94]) among females <20 years, with no indication of cross-protection or herd effects. Our results are promising for the long-term population-level impact of HPV vaccination programs. However, continued monitoring is essential to identify any signals of potential waning efficacy or type-replacement.
LanguageEnglish
Number of pages16
JournalLancet Infectious Diseases
Early online date3 Mar 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Vaccination
Meta-Analysis
Relative Risk
Population
Warts
Coverage
Cross Protection
Infection
Human papillomavirus 18
Human papillomavirus 16
Review
Human
Efficacy
Human papillomavirus 31
Trend Analysis
Papillomavirus Infections
Dose-response
Vaccine
Random Effects Model
Clinical Trials

Keywords

  • HPV vaccination
  • human papillomavirus
  • vaccination programmes

Cite this

Drolet, Melanie ; Benard, Elodie ; Boily, Marie-Claude ; Ali, Hammad ; Baandrup, Louise ; Bauer, Heidi ; Beddows, Simon ; Brisson, Jacques ; Brotherton, Julia M L ; Cummings, Teresa ; Donovan, Basil ; Fairley, Christopher K ; Flagg, Elaine W ; Johnson, Anne M ; Kahn, Jessica A ; Kavanagh, Kimberley ; Kjaer, Susanne K ; Kliewer, Erich V ; Lemieux-Mellouki, Philippe ; Markowitz, Lauri ; Mboup, Aminata ; Mesher, David ; Niccolai, Linda ; Oliphant, Jeannie ; Pollock, Kevin G ; Soldan, Kate ; Sonnenberg, Pam ; Tabrizi, Sepehr N ; Tanton, Clare ; Brisson, Marc. / Population-level impact and herd effects following human papillomavirus vaccination programs : a systematic review and meta-analysis. In: Lancet Infectious Diseases. 2015.
@article{7e4682add34d4e4c9f4a87d8c8fea093,
title = "Population-level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis",
abstract = "Human papillomavirus (HPV) vaccination programs were first implemented in 2007. We conducted a systematic review and meta-analysis to examine the population-level impact and herd effects following female HPV vaccination programs, to verify whether the high efficacy measured in randomized controlled clinical trials are materialising under real-world conditions. We searched Medline and Embase databases (01/2007-02/2014), and conference abstracts for time- trend studies examining changes, between the pre- and post-vaccination periods, in the incidence/prevalence of at least one HPV-related endpoint: HPV infection, anogenital warts (AGW), and high-grade cervical lesions. We derived pooled relative risk (RR) estimates using random effect models. We stratified all analyses by age and gender. We performed subgroups analysis by comparing studies according to vaccine type, vaccination coverage and years since vaccination implementation. We assessed heterogeneity across studies using I2 and χ2 statistics. We performed trends analysis to examine dose-response between HPV vaccination coverage and each study effect measure. We identified 20 eligible studies, conducted in nine high-income countries, and representing >140 million person-years of follow-up. In countries with female vaccination coverage ≥50{\%}, HPV-16/18 infections and AGW decreased significantly between the pre- and post-vaccination periods by 68{\%} (RR=0·32, 95{\%}CI[0·19;0·52]) and 61{\%} (RR=0·39, 95{\%}CI[0·22;0·71]), respectively, among females <20 years. Significant reductions in HPV-31/33/45 among females <20 years (RR=0·72, 95{\%}CI[0·54;0·96]), and AGW among males <20 years (RR=0·66, 95{\%}CI[0·47;0·91]) and older females (RR=0·68, 95CI[0·51;0·89]) were also observed, respectively suggesting cross-protection and herd effects. In countries with female vaccination coverage <50{\%}, significant reductions were observed for HPV-16/18 infection (RR=0·50, 95{\%}CI[0·34;0·74]) and AGW (RR=0·86, 95{\%}CI[0·79;0·94]) among females <20 years, with no indication of cross-protection or herd effects. Our results are promising for the long-term population-level impact of HPV vaccination programs. However, continued monitoring is essential to identify any signals of potential waning efficacy or type-replacement.",
keywords = "HPV vaccination, human papillomavirus, vaccination programmes",
author = "Melanie Drolet and Elodie Benard and Marie-Claude Boily and Hammad Ali and Louise Baandrup and Heidi Bauer and Simon Beddows and Jacques Brisson and Brotherton, {Julia M L} and Teresa Cummings and Basil Donovan and Fairley, {Christopher K} and Flagg, {Elaine W} and Johnson, {Anne M} and Kahn, {Jessica A} and Kimberley Kavanagh and Kjaer, {Susanne K} and Kliewer, {Erich V} and Philippe Lemieux-Mellouki and Lauri Markowitz and Aminata Mboup and David Mesher and Linda Niccolai and Jeannie Oliphant and Pollock, {Kevin G} and Kate Soldan and Pam Sonnenberg and Tabrizi, {Sepehr N} and Clare Tanton and Marc Brisson",
year = "2015",
doi = "10.1016/S1473-3099(14)71073-4",
language = "English",
journal = "Lancet Infectious Diseases",
issn = "1473-3099",

}

Drolet, M, Benard, E, Boily, M-C, Ali, H, Baandrup, L, Bauer, H, Beddows, S, Brisson, J, Brotherton, JML, Cummings, T, Donovan, B, Fairley, CK, Flagg, EW, Johnson, AM, Kahn, JA, Kavanagh, K, Kjaer, SK, Kliewer, EV, Lemieux-Mellouki, P, Markowitz, L, Mboup, A, Mesher, D, Niccolai, L, Oliphant, J, Pollock, KG, Soldan, K, Sonnenberg, P, Tabrizi, SN, Tanton, C & Brisson, M 2015, 'Population-level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis' Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(14)71073-4

Population-level impact and herd effects following human papillomavirus vaccination programs : a systematic review and meta-analysis. / Drolet, Melanie; Benard, Elodie; Boily, Marie-Claude; Ali, Hammad; Baandrup, Louise; Bauer, Heidi; Beddows, Simon; Brisson, Jacques; Brotherton, Julia M L; Cummings, Teresa; Donovan, Basil; Fairley, Christopher K; Flagg, Elaine W; Johnson, Anne M; Kahn, Jessica A; Kavanagh, Kimberley; Kjaer, Susanne K ; Kliewer, Erich V; Lemieux-Mellouki, Philippe; Markowitz, Lauri; Mboup, Aminata; Mesher, David ; Niccolai, Linda; Oliphant, Jeannie; Pollock, Kevin G; Soldan, Kate; Sonnenberg, Pam; Tabrizi, Sepehr N; Tanton, Clare; Brisson, Marc.

In: Lancet Infectious Diseases, 2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Population-level impact and herd effects following human papillomavirus vaccination programs

T2 - Lancet Infectious Diseases

AU - Drolet, Melanie

AU - Benard, Elodie

AU - Boily, Marie-Claude

AU - Ali, Hammad

AU - Baandrup, Louise

AU - Bauer, Heidi

AU - Beddows, Simon

AU - Brisson, Jacques

AU - Brotherton, Julia M L

AU - Cummings, Teresa

AU - Donovan, Basil

AU - Fairley, Christopher K

AU - Flagg, Elaine W

AU - Johnson, Anne M

AU - Kahn, Jessica A

AU - Kavanagh, Kimberley

AU - Kjaer, Susanne K

AU - Kliewer, Erich V

AU - Lemieux-Mellouki, Philippe

AU - Markowitz, Lauri

AU - Mboup, Aminata

AU - Mesher, David

AU - Niccolai, Linda

AU - Oliphant, Jeannie

AU - Pollock, Kevin G

AU - Soldan, Kate

AU - Sonnenberg, Pam

AU - Tabrizi, Sepehr N

AU - Tanton, Clare

AU - Brisson, Marc

PY - 2015

Y1 - 2015

N2 - Human papillomavirus (HPV) vaccination programs were first implemented in 2007. We conducted a systematic review and meta-analysis to examine the population-level impact and herd effects following female HPV vaccination programs, to verify whether the high efficacy measured in randomized controlled clinical trials are materialising under real-world conditions. We searched Medline and Embase databases (01/2007-02/2014), and conference abstracts for time- trend studies examining changes, between the pre- and post-vaccination periods, in the incidence/prevalence of at least one HPV-related endpoint: HPV infection, anogenital warts (AGW), and high-grade cervical lesions. We derived pooled relative risk (RR) estimates using random effect models. We stratified all analyses by age and gender. We performed subgroups analysis by comparing studies according to vaccine type, vaccination coverage and years since vaccination implementation. We assessed heterogeneity across studies using I2 and χ2 statistics. We performed trends analysis to examine dose-response between HPV vaccination coverage and each study effect measure. We identified 20 eligible studies, conducted in nine high-income countries, and representing >140 million person-years of follow-up. In countries with female vaccination coverage ≥50%, HPV-16/18 infections and AGW decreased significantly between the pre- and post-vaccination periods by 68% (RR=0·32, 95%CI[0·19;0·52]) and 61% (RR=0·39, 95%CI[0·22;0·71]), respectively, among females <20 years. Significant reductions in HPV-31/33/45 among females <20 years (RR=0·72, 95%CI[0·54;0·96]), and AGW among males <20 years (RR=0·66, 95%CI[0·47;0·91]) and older females (RR=0·68, 95CI[0·51;0·89]) were also observed, respectively suggesting cross-protection and herd effects. In countries with female vaccination coverage <50%, significant reductions were observed for HPV-16/18 infection (RR=0·50, 95%CI[0·34;0·74]) and AGW (RR=0·86, 95%CI[0·79;0·94]) among females <20 years, with no indication of cross-protection or herd effects. Our results are promising for the long-term population-level impact of HPV vaccination programs. However, continued monitoring is essential to identify any signals of potential waning efficacy or type-replacement.

AB - Human papillomavirus (HPV) vaccination programs were first implemented in 2007. We conducted a systematic review and meta-analysis to examine the population-level impact and herd effects following female HPV vaccination programs, to verify whether the high efficacy measured in randomized controlled clinical trials are materialising under real-world conditions. We searched Medline and Embase databases (01/2007-02/2014), and conference abstracts for time- trend studies examining changes, between the pre- and post-vaccination periods, in the incidence/prevalence of at least one HPV-related endpoint: HPV infection, anogenital warts (AGW), and high-grade cervical lesions. We derived pooled relative risk (RR) estimates using random effect models. We stratified all analyses by age and gender. We performed subgroups analysis by comparing studies according to vaccine type, vaccination coverage and years since vaccination implementation. We assessed heterogeneity across studies using I2 and χ2 statistics. We performed trends analysis to examine dose-response between HPV vaccination coverage and each study effect measure. We identified 20 eligible studies, conducted in nine high-income countries, and representing >140 million person-years of follow-up. In countries with female vaccination coverage ≥50%, HPV-16/18 infections and AGW decreased significantly between the pre- and post-vaccination periods by 68% (RR=0·32, 95%CI[0·19;0·52]) and 61% (RR=0·39, 95%CI[0·22;0·71]), respectively, among females <20 years. Significant reductions in HPV-31/33/45 among females <20 years (RR=0·72, 95%CI[0·54;0·96]), and AGW among males <20 years (RR=0·66, 95%CI[0·47;0·91]) and older females (RR=0·68, 95CI[0·51;0·89]) were also observed, respectively suggesting cross-protection and herd effects. In countries with female vaccination coverage <50%, significant reductions were observed for HPV-16/18 infection (RR=0·50, 95%CI[0·34;0·74]) and AGW (RR=0·86, 95%CI[0·79;0·94]) among females <20 years, with no indication of cross-protection or herd effects. Our results are promising for the long-term population-level impact of HPV vaccination programs. However, continued monitoring is essential to identify any signals of potential waning efficacy or type-replacement.

KW - HPV vaccination

KW - human papillomavirus

KW - vaccination programmes

UR - http://www.sciencedirect.com/science/article/pii/S1473309914710734

U2 - 10.1016/S1473-3099(14)71073-4

DO - 10.1016/S1473-3099(14)71073-4

M3 - Article

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

SN - 1473-3099

ER -